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Background: Recent studies have shown that some glycosyltransferases are involved in the development of
nonalcoholic fatty liver disease (NAFLD). The objective of this study was to explore the effect and mechanism of
glycosyltransferase GLT8D2 on fatty liver.
Methods: Rat model of NAFLD was established by induction with high-fat-diet. The GLT8D2 expression in rat liver
was examined using immunohistochemistry. Oil Red O staining and triglyceride assay were used to measure the
effect of abnormal GLT8D2 expression on lipid accumulation in HepG2 cells. The expression levels of lipid
metabolism-related key molecules, namely sterol regulatory element-binding protein-1c (SREBP-1c), stearoyl-coA
desaturase (SCD), carnitine palmitoyltransferase-1 (CPT1) and microsomal triglyceride transfer protein (MTP), in HepG2
cells with abnormal GLT8D2 expression were determined by western blot analyses.
Results: The expression of GLT8D2 was higher in the liver of rats with NAFLD than in the control rats, and GLT8D2 was
mainly located around lipid droplets in hepatocytes. GLT8D2 expression increased in steatosis HepG2 cells compared
with that in normal HepG2 cells. GLT8D2 positively regulated lipid droplet accumulation and triglyceride content in
HepG2 cells. Upregulation or knockdown of GLT8D2 had no effect on the expressions of SREBP-1c, SCD or
CPT-1 proteins in HepG2 cells. However, GLT8D2 expression negatively regulated the expression of MTP
protein in HepG2 cells.
Conclusion: GLT8D2 participated in NAFLD pathogenesis possibly by negatively regulating MTP expression.
Specific inhibition of GLT8D2 via an antagonistic strategy could provide a potential candidate approach for
treatment of NAFLD.
Keywords: Glycosyltransferase, GLT8D2, HepG2 cells, Fatty liverIntroduction
Non-alcoholic fatty liver disease (NAFLD) is one of the
most common types of liver disease in the world [1,2].
With an increase in obese population, the incidence of
NAFLD is expected to increase worldwide. The prevalence
of NAFLD in the US is expected to increase by 50% in
2030 [3]. Although previously being recognized as benign,
it is now clear that hepatic steatosis can evolve to more* Correspondence: yutaozhan@263.net; anwei@ccmu.edu.cn
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unless otherwise stated.severe liver damage [4], including non-alcoholic steatohe-
patitis (NASH), hepatic fibrosis/cirrhosis and hepato-
cellular carcinoma (HCC) [5-7]. Moreover, NAFLD can
promote the development and progression of diseases in
other organs [8]. Several studies have confirmed that
NAFLD is associated with high prevalence of cardiovas-
cular disease, and it is an independent risk factor for
cardiovascular disease in type 2 diabetes [9,10]. NAFLD
also significantly increases the risk of diabetes [11]. Cur-
rently, there is no effective treatment for NAFLD, there-
fore, it is essential to explore the possible mechanism of
NAFLD.
Glycosyltransferases constitute a large group of enzymes
that transfer one or multiple molecules of sugar to a
wide range of acceptor molecules such as lipids, proteins,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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[12]. These enzymes play key roles in many fundamental
biological processes underpinning human health and dis-
ease, such as cell signalling, cellular adhesion, carcinogen-
esis, and cell wall biosynthesis in human pathogens [13].
Recent studies have shown that some glycosyltransfer-
ases affect the development of fatty liver disease. Fu
et al. have reported that T-synthase (a glycosyltransfer-
ase) gene deficiency causes fatty liver disease in mice [14].
Ihara et al. have found that the transgenic mice expressing
N-acetylglucosaminyltransferase III developed readily a
fatty liver [15]. Recently, we have cloned a new glycosyl-
transferase gene GLT8D2 [16]. In the present study, we
examined the GLT8D2 expression in fatty liver of rat, and
the effect of aberrant expression of GLT8D2 on the
accumulation of triglyceride and the several key mole-
cules related to the accumulation of triglyceride in HepG2
cells.Materials and methods
Materials
Lipofectamine 2000 reagent was purchased from Life
Technologies (Carlsbad, CA,USA). Staining reagent of Oil
Red O was purchased from Sigma (St. Louis, MO, USA).
The triglyceride assay kit was obtained from Bioassay
Systems (Hayward, CA, USA). The anti-GLT8D2 antibody
was purchased from Santa Cruz(Santa Cruz, CA, USA). The
anti-SREBP1 (sterol regulatory element-binding protein-1c)
antibody, anti-MTP (microsomal triglyceride transfer pro-
tein) antibody, anti-CPT-1 (carnitine palmitoyltransferase-1)
antibody and anti-SCD antibody were from Abcam (Beijing,
China). Antibodies against His and GAPDH (glyceraldehyde-
3-phosphate dehydrogenase) were from Marine Biological
Laboratory (Beijing, China). Chemiluminescence kit for
signal detection of Western blot is the product of Thermo
Fisher (Boston, MA, USA). All other reagents were of ana-
lytical grade.Animal care
Male Sprague-Dawley (SD) rats weighed 150-180 g were
purchased from the Academy of Military Medical Sciences
(Beijing, China). Rats were randomly divided into two
groups: the model group and the control group (12 rats in
each group). A NAFLD rat model was established by feed-
ing the rats with the high-fat Lieber-DeCarli liquid diet
(energy 71% from fat, 11% from carbohydrates and 18%
from protein) for 7 weeks. SD rats in the control group
were fed the standard Lieber-DeCarli diet (energy 35%
from fat, 47% from carbohydrates and 18% from protein).
The diets were purchased from HFK bioscience company
(Beijing, China). All animal procedures were carried out
in accordance with the Animal Handling Guidelines of
Capital Medical University).Immunohistochemistry
SD rats were euthanized after 7 weeks, and the liver was
excised, fixed in 10% buffered formalin and embedded in
paraffin. Sections were prepared for immunohistochemi-
cal array. Unstained sections were deparaffinized and
rehydrated. After distilled water rinses, endogenous per-
oxidase was inactivated with 3% hydrogen peroxide for
3 min. The sections were then treated with 10 mM so-
dium citrate buffer (pH6.0) for 20 min for microwave anti-
gen retrieval. The slides were incubated with primary
antibody (anti- GLT8D2) in a moist chamber for 30 min
at 37°C. The antibody against GLT8D2 was used at a dilu-
tion of 1:1000. After rinsed in distilled water, the sections
were incubated with secondary antibody (goat anti-mouse
IgG) for 30 min at 37°C, and then incubated with S-A/HRP
at 37°C for 30 min. Signal development was performed
using 3,3-diaminobenzidin (DAB) as a chromogen. Sec-
tions were counterstained with hematoxylin and mounted
in glycergel. The negative control group was treated with
the same steps as described above, but the primary anti-
body was replaced by phosphate-buffered saline (PBS).
Cell culture and treatments
HepG2 cells were purchased from ATCC (Manassas,
VA, USA) and maintained at the Institute of Infectious
Disease, Capital Medical University. The cells were cul-
tured in the Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% fetal calf serum (FCS) in a 5%
CO2-humidified atmosphere at 37°C. HepG2 cells were
seeded in 6-well plates. Induction of steatosis was achieved
using a 100 μmol/L oleic acid (OA) solution dissolved in
0.01 mM NaOH. The duration of the treatment to induce
steatosis was 72 h. At 24 h after cell seeding, HepG2 cells
were used for transfection and RNA interference with or
without the incubation of OA for 72 h.
Transfection and RNA interference
The plasmid GLT8D2 was transfected into HepG2 cells
with Lipofectamine 2000 according to the manufacturer’s
instructions. According to our previous study [16], we se-
lected the strongest inhibitory GLT8D2 shRNA in this re-
search. The GLT8D2 shRNA (5′-TGCTGTCATGTTGG
CAACAATCACACGTTTTGGCCACTGACTGA CGTG
TGATTTGCCAACATGA-3′), and non-target control
shRNA (5′-TGCTGAAATGTACTGCGCGTGGAGACG
TTTTGGCCACTGACTG ACGTCTCCACGCAGTACA
TTT-3′) were synthesized by Life Technologies and trans-
fected into HepG2 cells using Lipofectamine 2000. 72 h
post transfection, the cells were collected for further
analysis.
Oil Red O staining
HepG2 cells were grown on a coverslip, washed with
phosphate-buffered saline and then fixed with 10% formalin
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were washed gently with 60% isopropanol and stained with
the working solution of 0.5 g Oil Red O in 60% isopropanol
for 15 min. The stained hepatocytes were washed with dis-
tilled water several times to remove unincorporated dye.
Then, the samples were counterstained with hematoxylin
for 5 min. Results were examined using a light microscope.
Intracellular triglyceride content assay
HepG2 cells were pre-incubated in 25-cm2 cell culture
flasks for 18-24 h and then transfected with his-GLT8D2
plasmid and GLT8D2 shRNA, respectively. The cells were
cultured in DMEM with or without OA. After 72 h of in-
cubation, cells were collected and centrifuged at 1000 g
for 5 min. Cell pellets were washed with PBS once, resus-
pended in 400 μL PBS buffer and transferred to a micro-
smashing tube for ultrasonication. After ultrasonication,
the concentration of cellular triglyceride was determined
using an EnzyChrom™ triglyceride assay kit (Bioassay Systems,
Hayward, CA, USA) and normalized with protein concentra-
tion according to the protocol provided by the manufacturer.
Western blot analysis
Cells were lyzed in HEPES [N-(2-hydroxyethyl) piperazine-
N’-2-ethanesulfonic acid] lysis buffer (20 mM HEPES,
50 mM NaCl, 0.5% Triton X-100, 1 mM NaF and 1 mM
dithiothreitol). Protein from each sample was separated by
10% SDS-PAGE and electrotransferred to nitrocellulose fil-
ter membranes. The membranes were blocked with 5%
BSA in TBS for 1 h at room temperature and incubated
overnight at 4°C using the indicated primary antibodies,
followed by detection with the related secondary antibody
and the Super Signal chemiluminescence kit (Thermo
Fisher).
Statistical analysis
Data are expressed as mean ± SD. The significance of
differences was determined by t-test using the SPSS
17.0 software (SPSS, Chicago, IL, USA). Difference
with a p value of less than 0.05 was considered statisti-
cally significant.Figure 1 Successful inducement of rat NAFLD models. Specimens of rat liv
was found in control rat liver. (B) hepatocyte steatosis was obvious in NAFResults
Inducement of NAFLD in rat model
No obvious steatosis was found in hepatocytes in rats in
the control group. In contrast, there were a lot of steatotic
hepatocytes in rats in the high-fat diet group (Figure 1).
This suggested that the rat NAFLD model was established
successfully.
Expression of GLT8D2 in liver of rats with NAFLD
Immunohistochemical results of GLT8D2 in liver showed
that the GLT8D2 expression was scattered in the rat liver
of the control group. The expression of GLT8D2 was
higher in the high-fat-diet animals than the control ones.
In addition, GLT8D2 was obviously expressed surrounding
the lipid droplets in the steatotic hepatocytes (Figure 2).
Expression of GLT8D2 in HepG2 cells with steatosis
A cell model of steatosis in vitro was induced in HepG2
cells with OA at 100 μmol/L. After incubation for 72 h, OA
treatment significantly increased the protein expression of
GLT8D2 in HepG2 cells (Figure 3).
GLT8D2 affected lipid accumulation in HepG2 cells
In order to investigate whether GLT8D2 affected hepato-
cyte steatosis, HepG2 cells were transfected with his-
GLT8D2 plasmid or GLT8D2 shRNA, respectively, and
cultured continuously under non-fat-loading and fat-loading
conditions. Lipid accumulation was examined after Oil
Red O staining. As shown in Figure 4, under the non-fat-
loading and fat-loading conditions, the overexpression of
GLT8D2 correlated with an increase in the amount of lipid
droplets in HepG2 cells. However, knockdown of GLT8D2
by shRNA could reverse or alleviate the lipid droplet
accumulation in hepatocytes as compared with GLT8D2
transfection. To quantify the effect of GLT8D2 on lipid ac-
cumulation, we next measured triglyceride concentration
in cell lysate. In GLT8D2-overexpressing HepG2 cells, the
levels of triglyceride in cells cultured under fat-loaded
conditions was increased by 7.6% and 10.4%, respectively
(Figure 5A). In contrast, the average intracellular trigly-
ceride concentration in cells with GLT8D2 knockdowner were stained with HE (×200). (A) No obvious hepatocyte steatosis
LD model rat liver.
Figure 2 The expression of GLT8D2 in rat livers. GLT8D2 expression in rat livers was detected by immunohistochemistry (×400). (A) GLT8D2
expression was scattered in control rat liver. (B) GLT8D2 expression increased in NAFLD rat liver. GLT8D2 expression surrounded mainly the lipid
droplets. Rat NAFLD model was induced by Lieber-DeCarli liquid diet for 7 weeks.
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trol cells under the fat-loading conditions, respectively
(Figure 5B). These data suggested that GLT8D2 positively
regulated lipid accumulation in HepG2 cells.
Regulation of proteins involved in lipid homeostasis by
GLT8D2
To elucidate the mechanism of the effect of GLT8D2 on
hepatocyte steatosis, we next examined the expressions
of proteins involved in lipid homeostasis after GLT8D2
overexpression or knockdown (Figure 6). Microsomal tri-
glyceride transfer protein (MTP) is an essential factor for
very low density lipoproteins (VLDL) assembly and secre-
tion. VLDL is the major lipoproteins responsible for trans-
porting triglyceride from the liver to extra-hepatic tissues.
Significant down-regulation of MTP in HepG2 cells was
observed when GLT8D2 was overexpressed under both
non-fat-loading and fat-loading conditions. Conversely,
GLT8D2 knockdown increased MTP expression in HepG2
cells under both non-fat-loading and fat-loading conditions.
Those results suggested that MTP could be a potential
impaired molecule by GLT8D2 during intracellular lipidFigure 3 The effect of OA on GLT8D2 expression in HepG2 cells. HepG2 ce
collected for western blot analysis. The GLT8D2 expression in HepG2 cells iexcretion. Other lipid synthesis and metabolism-related
molecules, such as SREBP-1c, SCD proteins, and even CPT-
11, one of the rate-limiting enzymes of the mitochondrial
fatty acid β-oxidation pathway, seem not to be affected by
GLT8D2.
Discussion
Glycosyltransferases encompass 1% of all sequenced ge-
nomes [17]. There are over 65,000 glycosyltransferase se-
quences within the Carbohydrate-Active enzyme data base
in 2011, comprising 89 families based on sequence similarity
[13]. There are 105 glycosyltransferase structures in the
Protein Data Bank [13]. To date, there 97 CAZy glycosyl-
transferase families (CAZy, http://www.cazy.org/Glycosyl-
Transferases.html). As a member of the glycosyltransferase
8 family, the human GLT8D2 is a 349 amino acid single-
pass type II membrane protein encoded by a gene located
on chromosome 12q23.3. The first six amino acid residues
extend to the cytoplasm, residues 7-24 are the transmem-
brane domain resided in the cell membrane; and residues
25-349 are in the luminal compartments [16]. Moylan et al.
have reported that the GLT8D2 gene is up-regulated inlls were treated with 0, 100 and 200 μM OA for 72 h, and then
ncreased with the increase of OA concentration.
Figure 4 The effect of GLT8D2 abnormality on intracellular lipid droplet in HepG2 cells. Intracellular lipid droplet was tested by staining with Oil
Red O. Enhanced GLT8D2 for 72 h increased lipid droplet accumulation in HepG2 cells with or without OA, especially in HepG2 cells with OA.
Inhibitory GLT8D2 for 72 decreased lipid accumulation in HepG2 cells with OA. (A) HepG2 cells. (B) HepG2 cells with GLT8D2 transfection. (C)
HepG2 cells GLT8D2 RNA interference. (D) HepG2 cells with OA. (E) HepG2 cells with OA and GLT8D2 transfection. (F) HepG2 cells with OA and
GLT8D2 RNA interference.
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found that GLT8D2 expression increased in fatty liver of
rats compared with normal liver, and that GLT8D2 was
mainly expressed around lipid droplets. In the in vitro
study, we also found that GLT8D2 expression increased in
steatosis HepG2 cells compared with normal HepG2 cells.
Further study showed that high GLT8D2 expression
increases the accumulation of triglyceride in HepG2 cells.
These data suggested that GLT8D2 might play an import-
ant role in the pathogenesis of NAFLD.
NAFLD is characterized by the excessive accumulation
of triglyceride in hepatocytes [18]. Triglyceride is formed
through the esterification of free fatty acids (FFAs) and
glycerol. FFAs arise in the liver from three distinct sources
[19]: (a) recirculation of non-esterified fatty acids from per-
ipheral tissues (some from adipose tissues and some from
skeletal muscle); (b) de novo lipogenesis (DNL) within
hepatocytes and (c) dietary sources. Adipose tissue is the
main source of liver FFAs. Approximately 60% of liver tri-
glyceride is derived from FFA influx from the adipose tis-
sue, 25% are from DNL, and 15% are from diet [20]. FFAs
in liver have three major fates. They can be β-oxidized inFigure 5 The effect of GLT8D2 abnormality on triglyceride content in Hep
cells with or without OA. (B) Inhibitory GLT8D2 decreased triglyceride cont
*p < 0.05 compared with cells with normal GLT8D2, respectively.mitochondria to produce energy and ketone bodies, re-
esterified to triglyceride and stored in lipid droplets, or
coupled to apolipoproteins and secreted as a constituent
of VLDL [21]. Hence, hepatic fat accumulation can occur
as a result of increased triglyceride synthesis, decreased
FFAs oxidation and/or decreased fat export. DNL is con-
trolled primarily at the transcriptional level [22,4]. Sterol
regulatory element-binding protein-1c (SREBP-1c) is a
major transcription factor that promotes the expression of
lipogenic genes. It can activate all genes required for lipo-
genesis, such as SCD [23]. SCD is a key enzyme of fatty
acid biosynthesis. Mitochondrial fatty acid β-oxidation is
controlled by carnitine palmitoyltransferase-1 (CPT-1).
CPT-1 is the rate-limiting enzyme of the mitochondrial
fatty acid β-oxidation pathway [24,25]. Fatty acids are acti-
vated to form fatty acyl-CoAs. CPT-1 catalyzes the conver-
sion of acyl-CoA to acyl-carnitine, which then enters into
the mitochondria for fatty acid β-oxidation [26]. VLDL
is the major lipoproteins transporting triglyceride from
the liver to extrahepatic tissues [27]. It is assembled in
endoplasmic reticulum in hepatic cells [28]. Each VLDL
particle is stabilized by a single molecule of apolipoproteinG2 cells. (A) Enhanced GLT8D2 increased triglyceride content in HepG2
ent in HepG2 cells with OA. Data are expressed as means ± SD (n = 6);
Figure 6 The effect of GLT8D2 abnormality on the expressions of lipid synthesis and metabolism-related molecules (SREBP-1c, SCD, MTP and
CPT-1). (A) Enhanced GLT8D2 decreased MTP expression in HepG2 cells with or without OA. Enhanced GLT8D2 has not obvious affect on the
SREBP-1c, SCD and CPT-1 expressions in HepG2 cells with or without OA. (B) Inhibitory GLT8D2 increased MTP expression in HepG2 cells
with or without OA. Inhibitory GLT8D2 has not obvious affect on the SREBP-1c, SCD and CPT-1 expressions in HepG2 cells with or
without OA. Data are expressed as mean ± SD (n = 6); *p < 0.05 compared with cells with normal GLT8D2, respectively. White square
without GLT8D2 and without OA. Light gray square with GLT8D2 and without OA. Dark gray square without GLT8D2 and with OA. Black
square with GLT8D2 and with OA.
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is lipidated with triglycerides within the lumen of ER
while it is being translated and translocated across the
ER membrane.
MTP has both apoB 100 binding and lipid transfer do-
mains [29]. MTP is an essential factor for VLDL assem-
bly and secretion. To explore the effective molecules
response to GLT8D2 in the accumulation of triglyceride
in hepatocytes, we investigated the alternations of sev-
eral key molecules related to the hepatic lipid accumula-
tion as mentioned above. We found that the transfection
of GLT8D2 gene did not affect the expressions of
SREBP-1c, SCD and CPT1, but actually decreased the
MTP expression in HepG2 cells, and inhibitory GLT8D2
increased MTP expression in HepG2 cells. Combined
with our previous results that GLT8D2 up-regulates the
levels of apoB100 protein in HepG2 cells [16], we specu-
late that the inhibition of MTP expression by GLT8D2
may be the major mechanism resulting in accumulation of
triglyceride in HepG2 cells. The detail mechanisms of
GLT8D2 regulating MTP are still unknown thus need fur-
ther study.
Based on these results, we conclude that the impair-
ment of MTP function by GLT8D2 is attributed to the
enhanced accumulation of triglyceride in hepatocytes
during development of NAFLD, and specific inhib-
ition of GLT8D2 via an antagonistic strategy could pro-
vide a potential candidate approach for treatment of
NAFLD.Abbreviations
apoB 100: Apolipoprotein B100; CPT1: Carnitine palmitoyltransferase-1;
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